33,163 Shares in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Purchased by Walleye Capital LLC

Walleye Capital LLC bought a new stake in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPTGet Rating) during the first quarter, HoldingsChannel reports. The institutional investor bought 33,163 shares of the biopharmaceutical company’s stock, valued at approximately $540,000.

Other large investors also recently added to or reduced their stakes in the company. Fuller & Thaler Asset Management Inc. raised its stake in shares of Intercept Pharmaceuticals by 0.5% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 164,210 shares of the biopharmaceutical company’s stock worth $2,672,000 after buying an additional 825 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Intercept Pharmaceuticals by 1.0% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 156,715 shares of the biopharmaceutical company’s stock worth $2,550,000 after acquiring an additional 1,607 shares during the period. Virginia Retirement Systems ET AL raised its position in shares of Intercept Pharmaceuticals by 5.0% during the 1st quarter. Virginia Retirement Systems ET AL now owns 37,900 shares of the biopharmaceutical company’s stock valued at $617,000 after acquiring an additional 1,800 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Intercept Pharmaceuticals by 63.9% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,879 shares of the biopharmaceutical company’s stock valued at $79,000 after purchasing an additional 1,903 shares during the period. Finally, New York State Common Retirement Fund boosted its position in shares of Intercept Pharmaceuticals by 13.4% in the 1st quarter. New York State Common Retirement Fund now owns 19,430 shares of the biopharmaceutical company’s stock worth $316,000 after purchasing an additional 2,293 shares during the last quarter. 86.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ICPT has been the subject of a number of recent analyst reports. Raymond James upped their price objective on Intercept Pharmaceuticals from $23.00 to $26.00 and gave the company an “outperform” rating in a report on Thursday, August 4th. HC Wainwright cut their price target on shares of Intercept Pharmaceuticals from $18.00 to $16.00 and set a “neutral” rating on the stock in a research report on Monday, August 8th. SVB Leerink decreased their price objective on shares of Intercept Pharmaceuticals from $27.00 to $21.00 and set a “market perform” rating for the company in a report on Friday, July 8th. Cowen lowered their target price on shares of Intercept Pharmaceuticals to $22.00 in a research note on Tuesday, August 9th. Finally, StockNews.com lowered shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 4th. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $22.10.

Intercept Pharmaceuticals Trading Down 16.9 %

ICPT opened at $14.85 on Thursday. The stock has a market capitalization of $442.50 million, a P/E ratio of -6.84 and a beta of 1.09. Intercept Pharmaceuticals, Inc. has a 12 month low of $10.81 and a 12 month high of $21.25. The firm’s fifty day simple moving average is $16.37 and its 200 day simple moving average is $16.03.

Intercept Pharmaceuticals (NASDAQ:ICPTGet Rating) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.15). The business had revenue of $100.40 million during the quarter, compared to analysts’ expectations of $94.85 million. On average, equities research analysts predict that Intercept Pharmaceuticals, Inc. will post -2.92 EPS for the current fiscal year.

About Intercept Pharmaceuticals

(Get Rating)

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.

Recommended Stories

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPTGet Rating).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.